JPWO2023170554A5 - - Google Patents

Info

Publication number
JPWO2023170554A5
JPWO2023170554A5 JP2024553421A JP2024553421A JPWO2023170554A5 JP WO2023170554 A5 JPWO2023170554 A5 JP WO2023170554A5 JP 2024553421 A JP2024553421 A JP 2024553421A JP 2024553421 A JP2024553421 A JP 2024553421A JP WO2023170554 A5 JPWO2023170554 A5 JP WO2023170554A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
aticaplant
weight
composition
glidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508069A (ja
JP2025508069A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/052097 external-priority patent/WO2023170554A1/en
Publication of JP2025508069A publication Critical patent/JP2025508069A/ja
Publication of JPWO2023170554A5 publication Critical patent/JPWO2023170554A5/ja
Publication of JP2025508069A5 publication Critical patent/JP2025508069A5/ja
Pending legal-status Critical Current

Links

JP2024553421A 2022-03-07 2023-03-06 アチカプラントを含む組成物 Pending JP2025508069A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317471P 2022-03-07 2022-03-07
US63/317,471 2022-03-07
PCT/IB2023/052097 WO2023170554A1 (en) 2022-03-07 2023-03-06 Compositions comprising aticaprant

Publications (3)

Publication Number Publication Date
JP2025508069A JP2025508069A (ja) 2025-03-21
JPWO2023170554A5 true JPWO2023170554A5 (https=) 2026-02-18
JP2025508069A5 JP2025508069A5 (https=) 2026-02-18

Family

ID=85980700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553421A Pending JP2025508069A (ja) 2022-03-07 2023-03-06 アチカプラントを含む組成物

Country Status (15)

Country Link
US (3) US20230277500A1 (https=)
EP (1) EP4489730B1 (https=)
JP (1) JP2025508069A (https=)
KR (1) KR20240152410A (https=)
CN (1) CN119156202A (https=)
AU (1) AU2023231767A1 (https=)
CA (1) CA3254546A1 (https=)
CL (1) CL2024002648A1 (https=)
CO (1) CO2024012454A2 (https=)
IL (1) IL315415A (https=)
JO (1) JOP20240196A1 (https=)
MX (1) MX2024010977A (https=)
TW (1) TW202400135A (https=)
UY (1) UY40173A (https=)
WO (1) WO2023170554A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
TR200103237T2 (tr) 1999-05-12 2002-04-22 F. Hoffmann-La Roche Ag İmidazodiazepin türevi
US20020052365A1 (en) 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
ATE406360T1 (de) 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
EP1613597B1 (en) 2003-03-07 2007-11-07 Eli Lilly and Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
CA2549009A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
ES2390459T3 (es) 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides
DE602005022572D1 (de) 2004-03-12 2010-09-09 Lilly Co Eli Antagonisten des opioidrezeptors
ATE399164T1 (de) 2004-03-12 2008-07-15 Lilly Co Eli Antagonisten des opioidrezeptors
EP1729759A4 (en) 2004-03-12 2008-04-02 Mclean Hospital Corp SALVINORINE DERIVATIVES AND ITS USES
DE602005012380D1 (de) 2004-03-15 2009-03-05 Lilly Co Eli 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
EP1735268B1 (en) 2004-03-15 2012-02-15 Eli Lilly And Company Opioid receptor antagonists
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
JP5128578B2 (ja) 2006-04-04 2013-01-23 エモディス ゲーエムベーハー 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用
EP2049481A2 (en) 2006-08-09 2009-04-22 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
EP2054383A2 (en) 2006-08-09 2009-05-06 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
AU2010316683B2 (en) * 2009-11-09 2015-10-08 Wyeth Llc Tablet formulations of neratinib maleate
WO2012016569A1 (en) 2010-08-05 2012-02-09 Conrig Pharma Aps Deuterated tandospirone derivatives as 5-ht1a receptor agonists
ES2631607T3 (es) 2011-12-09 2017-09-01 Research Triangle Institute, International 4-Arilpiperazinas 1-sustituidas como antagonistas del receptor opioide kappa
ES2694352T3 (es) 2013-12-20 2018-12-20 H. Lundbeck A/S Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas
WO2016156396A1 (en) 2015-03-30 2016-10-06 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and methods for their production
US10709685B2 (en) 2015-05-28 2020-07-14 Georgetown University Use of methadone metabolites for treatment of anxiety and depression
CA2987912C (en) * 2015-06-30 2023-01-24 Genentech, Inc. Immediate-release tablets containing a drug and processes for forming the tablets
EP3468540A4 (en) 2016-06-13 2020-03-18 Board Of Regents Of the University Of Texas System PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
US20190240293A1 (en) 2016-07-26 2019-08-08 Flagship Pioneering Innovations V, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response
US11292783B2 (en) 2016-09-16 2022-04-05 Research Triangle Institute Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
AU2018234931B2 (en) 2017-03-17 2022-05-26 Blackthorn Therapeutics, Inc. Kappa opioid receptor antagonists and products and methods related thereto
PH12018000077B1 (en) * 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20190255036A1 (en) 2018-02-16 2019-08-22 Alexander Kariman Compound and method for reducing neuropathic pain and depression
JP7416751B2 (ja) 2018-03-23 2024-01-17 ユニバーシティ オブ カンザス 環状テトラペプチド類似体
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
EP3870030A4 (en) 2018-10-23 2022-08-03 Blackthorn Therapeutics, Inc. SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS
US20200171025A1 (en) * 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
PH12023552963A1 (en) * 2021-05-04 2024-03-11 Janssen Pharmaceuticals Inc Compositions and methods for the treatment of depression
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
AU2023231493A1 (en) 2022-03-07 2024-10-24 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant

Similar Documents

Publication Publication Date Title
DK2317997T3 (en) The low dose topiramate / phentermine-COMPOSITION AND METHODS THEREOF FOR USE
US8512751B2 (en) Pharmaceutical compositions for sleep disorders
ES2935800T3 (es) Forma de dosificación oral de ketamina
JP2017061561A (ja) ニタゾキサニドの制御放出医薬配合物
JP2010530422A (ja) うつ病のための組合せ治療
AU2001272243A1 (en) Rapid onset formulation
JP7364568B2 (ja) 持続放出ミドドリン塩酸塩組成物及び使用方法
CN104220068A (zh) 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物
JP4041460B2 (ja) セチリジン及びプソイドエフェドリンを含む錠剤
CA2858522A1 (en) Methods for treating cardiovascular disorder
US20240024263A1 (en) Methods of administering gamma-hydroxybutyrate compositions with divalproex sodium
EP2241310A2 (en) Modified release formulations of emoxypine
WO2019073477A1 (en) PHARMACEUTICAL COMPOSITION OF APREMILAST WITH EXTENDED RELEASE
JP2019529570A (ja) ミドドリンの組成物およびその使用方法
WO2021129735A1 (zh) 一种固体制剂及其制备方法和用途
WO2019203752A2 (en) Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent
CN104203240A (zh) 用于治疗精神疾病的伊潘立酮代谢物
JP7558593B2 (ja) イブプロフェン制御放出錠及びその調製方法
CN102112115A (zh) 雷米普利调节释放组合物及其应用
JPWO2023170554A5 (https=)
JP2014508187A (ja) 選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
KR20200013719A (ko) 레모글리플로진의 경구 약학적 제제
JP2015503555A (ja) ボセンタン制御放出性経口製剤
CA2902665C (en) Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
WO2010010136A1 (en) Pharmaceutical composition comprising pramipexole and an anti-inflammatory agent for the treatment of parkinson's disease